Tandem Diabetes Care CEO granted 191,103 RSUs

Sheridan John F reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Sheridan John F reported acquisition or exercise transactions in this Form 4 filing.

Tandem Diabetes Care reported that President and CEO John F. Sheridan received a grant of 191,103 restricted stock units (RSUs). Each RSU represents the right to receive one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan.

One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, encouraging longer-term alignment between the CEO and shareholders.

Insider Trade Summary

Grant/Award: 191,103 shares

Grant/Award 1 txn

Insider Sheridan John F

Role PRESIDENT & CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	191,103	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 191,103 contracts (Direct)

Footnotes (2)

F1. Each restricted stock unit (RSU) represents a contingent right to receive either one share of the Issuer's common stock or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F2. One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter.

Key Figures

RSUs granted: 191,103 units RSU vesting start date: May 29, 2027 Vesting structure: 8 quarterly installments +2 more

5 metrics

RSUs granted 191,103 units Grant to President & CEO John F. Sheridan

RSU vesting start date May 29, 2027 One-third of RSUs vest on this date

Vesting structure 8 quarterly installments Remaining RSUs vest in eight equal quarterly tranches

Exercise/settlement price $0.00 per unit RSUs granted with no exercise cost to holder

Security type Restricted Stock Unit Derivative security settling into common stock or cash

Key Terms

Restricted Stock Unit, contingent right, Long-Term Incentive Plan, vesting

4 terms

Restricted Stock Unit financial

"Each restricted stock unit (RSU) represents a contingent right to receive either one share..."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"Each restricted stock unit (RSU) represents a contingent right to receive either one share..."

Long-Term Incentive Plan financial

"in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan..."

A long-term incentive plan is a company program that pays executives or employees with stock, options, or cash tied to multi-year performance goals, where the rewards become theirs only after meeting conditions over time. Think of it as a delayed bonus or retirement-style reward that aligns employees’ interests with shareholders by encouraging them to boost long-term value; investors watch these plans because they affect pay costs, share dilution and management incentives.

vesting financial

"One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tandem Diabetes Care (TNDM) disclose?

Tandem Diabetes Care disclosed that President and CEO John F. Sheridan received a grant of 191,103 restricted stock units. These RSUs are part of his equity compensation and settle in common stock or cash under the company’s 2023 Long-Term Incentive Plan.

How many RSUs did TNDM CEO John F. Sheridan receive in this Form 4?

John F. Sheridan received 191,103 restricted stock units. Each RSU represents a contingent right to one share of Tandem Diabetes Care common stock or cash, granted at no exercise cost under the 2023 Long-Term Incentive Plan and related award agreements.

When do John F. Sheridan’s 191,103 RSUs at Tandem Diabetes Care vest?

One-third of the 191,103 RSUs will vest on May 29, 2027. The remaining RSUs vest in eight equal quarterly installments on the 15th of the month thereafter, creating a multi‑year vesting schedule tied to continued service and performance.

What does each Tandem Diabetes Care RSU granted to the CEO represent?

Each RSU represents a contingent right to receive one share of Tandem Diabetes Care common stock or cash. Settlement form is at the company’s discretion, following the terms of its 2023 Long‑Term Incentive Plan and the specific award agreements governing this grant.

Is the TNDM CEO’s RSU grant an open‑market stock purchase or sale?

The RSU grant is not an open‑market trade; it is an equity award classified as a grant or award acquisition. The CEO did not buy or sell shares in the market but received compensation units that may settle in stock or cash when they vest.

Under which plan were John F. Sheridan’s RSUs at Tandem Diabetes Care granted?

The RSUs were granted under the Tandem Diabetes Care, Inc. 2023 Long‑Term Incentive Plan, as amended. This plan governs the terms of equity awards, including vesting, settlement mechanics, and whether the company delivers common stock or cash on vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/02/2026 - 04:21 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sheridan John F

(Last)

(First)

(Middle)

12400 HIGH BLUFF DRIVE

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	05/29/2026		A		191,103		⁽²⁾	⁽²⁾	Common Stock	191,103	$0	191,103	D

Explanation of Responses:

1. Each restricted stock unit (RSU) represents a contingent right to receive either one share of the Issuer's common stock or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

2. One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter.

Remarks:

Ex. 24: Power of Attorney

	/s/ Jerilyn Laskie, Attorney-in-Fact for John F. Sheridan	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR